AxoGen Stock Price, News & Analysis (NASDAQ:AXGN)

$28.50 +0.75 (+2.70 %)
(As of 02/21/2018 04:00 PM ET)
Previous Close$27.75
Today's Range$27.80 - $28.75
52-Week Range$9.55 - $31.70
Volume227,274 shs
Average Volume287,259 shs
Market Capitalization$934.17 million
P/E Ratio-71.25
Dividend YieldN/A
Beta0.12

About AxoGen (NASDAQ:AXGN)

AxoGen logoAxoGen, Inc. provides surgical solutions for peripheral nerve injuries. The company’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed. In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.

Receive AXGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AXGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Appliances & Equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AXGN
CUSIPN/A
Phone386-462-6800

Debt

Debt-to-Equity Ratio1.93%
Current Ratio3.55%
Quick Ratio2.95%

Price-To-Earnings

Trailing P/E Ratio-71.25
Forward P/E Ratio-89.06
P/E GrowthN/A

Sales & Book Value

Annual Sales$41.11 million
Price / Sales23.63
Cash FlowN/A
Price / CashN/A
Book Value$0.45 per share
Price / Book63.33

Profitability

Trailing EPS($0.40)
Net Income$-14,410,000.00
Net Margins-24.74%
Return on Equity-91.00%
Return on Assets-25.48%

Miscellaneous

Employees146
Outstanding Shares34,090,000

AxoGen (NASDAQ:AXGN) Frequently Asked Questions

What is AxoGen's stock symbol?

AxoGen trades on the NASDAQ under the ticker symbol "AXGN."

How were AxoGen's earnings last quarter?

AxoGen, Inc. (NASDAQ:AXGN) posted its quarterly earnings results on Wednesday, November, 1st. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.06). The medical equipment provider had revenue of $16.05 million for the quarter, compared to analyst estimates of $15.55 million. AxoGen had a negative net margin of 24.74% and a negative return on equity of 91.00%. AxoGen's revenue for the quarter was up 43.2% compared to the same quarter last year. View AxoGen's Earnings History.

Where is AxoGen's stock going? Where will AxoGen's stock price be in 2018?

7 Wall Street analysts have issued 1 year target prices for AxoGen's shares. Their predictions range from $21.00 to $37.00. On average, they expect AxoGen's stock price to reach $29.33 in the next twelve months. View Analyst Ratings for AxoGen.

Who are some of AxoGen's key competitors?

Who owns AxoGen stock?

AxoGen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Essex Woodlands Management Inc. (10.89%), BlackRock Inc. (5.24%), Bank of New York Mellon Corp (2.49%), Driehaus Capital Management LLC (1.97%), Next Century Growth Investors LLC (1.96%) and Renaissance Technologies LLC (1.93%). Company insiders that own AxoGen stock include Amy Mcbride Wendell, Guido J Neels, James E Flynn, Jamie Mark Grooms, John P Engels, Joseph M Mandato, Karen L Zaderej, Peter J Mariani and Robert James Rudelius. View Institutional Ownership Trends for AxoGen.

Who sold AxoGen stock? Who is selling AxoGen stock?

AxoGen's stock was sold by a variety of institutional investors in the last quarter, including Essex Woodlands Management Inc., Deutsche Bank AG, Millennium Management LLC, Cortina Asset Management LLC, EAM Investors LLC, AWM Investment Company Inc., Millrace Asset Group Inc. and Suffolk Capital Management LLC. Company insiders that have sold AxoGen company stock in the last year include Guido J Neels, Jamie Mark Grooms and Robert James Rudelius. View Insider Buying and Selling for AxoGen.

Who bought AxoGen stock? Who is buying AxoGen stock?

AxoGen's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Wells Fargo & Company MN, Renaissance Technologies LLC, Bank of New York Mellon Corp, William Blair Investment Management LLC, Monashee Investment Management LLC, Rock Springs Capital Management LP and Jefferies Group LLC. Company insiders that have bought AxoGen stock in the last two years include Amy Mcbride Wendell, John P Engels, Karen L Zaderej and Peter J Mariani. View Insider Buying and Selling for AxoGen.

How do I buy AxoGen stock?

Shares of AxoGen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AxoGen's stock price today?

One share of AxoGen stock can currently be purchased for approximately $28.50.

How big of a company is AxoGen?

AxoGen has a market capitalization of $934.17 million and generates $41.11 million in revenue each year. The medical equipment provider earns $-14,410,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. AxoGen employs 146 workers across the globe.

How can I contact AxoGen?

AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider can be reached via phone at 386-462-6800 or via email at [email protected]


MarketBeat Community Rating for AxoGen (AXGN)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  161 (Vote Outperform)
Underperform Votes:  77 (Vote Underperform)
Total Votes:  238
MarketBeat's community ratings are surveys of what our community members think about AxoGen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AxoGen (NASDAQ:AXGN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $29.33$29.33$24.40$15.90
Price Target Upside: 10.07% upside5.53% downside0.41% upside2.25% upside

AxoGen (NASDAQ:AXGN) Consensus Price Target History

Price Target History for AxoGen (NASDAQ:AXGN)

AxoGen (NASDAQ:AXGN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/5/2018William BlairInitiated CoverageOutperformHighView Rating Details
1/8/2018Cantor FitzgeraldSet Price TargetBuy$37.00HighView Rating Details
11/30/2017Jefferies GroupInitiated CoverageBuy -> Buy$35.00HighView Rating Details
11/21/2017Leerink SwannBoost Price TargetOutperform -> Outperform$26.00 -> $30.00N/AView Rating Details
11/21/2017Lake Street CapitalBoost Price TargetBuy -> Buy$22.00 -> $26.00N/AView Rating Details
11/21/2017WedbushReiterated RatingBuy$22.00 -> $27.00N/AView Rating Details
9/12/2017Roth CapitalReiterated RatingBuy$18.00 -> $21.00LowView Rating Details
11/22/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

AxoGen (NASDAQ:AXGN) Earnings History and Estimates Chart

Earnings by Quarter for AxoGen (NASDAQ:AXGN)

AxoGen (NASDAQ AXGN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017Q3 2017($0.06)($0.06)$15.55 million$16.05 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.08)($0.06)$14.40 million$15.20 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.10)($0.11)$11.83 million$12.24 millionViewListenView Earnings Details
2/22/2017Q4 2016($0.09)($0.10)$11.41 millionViewListenView Earnings Details
11/2/2016Q3 2016($0.08)($0.08)$11.21 million$11.21 millionViewN/AView Earnings Details
8/3/2016Q2($0.12)($0.09)$9.28 million$10.38 millionViewN/AView Earnings Details
5/4/2016Q1 2016($0.13)($0.12)$7.74 million$8.11 millionViewN/AView Earnings Details
2/29/2016Q4 2015($0.11)($0.12)$7.13 million$7.81 millionViewN/AView Earnings Details
11/5/2015Q3 2015($0.12)($0.11)$6.70 million$8.15 millionViewN/AView Earnings Details
8/6/2015Q2 2015($0.15)($0.13)$5.89 million$6.42 millionViewN/AView Earnings Details
5/5/2015Q1 2015($0.17)($0.16)$4.90 million$4.95 millionViewN/AView Earnings Details
3/5/2015Q4 2014($0.18)($0.36)$4.74 million$4.79 millionViewN/AView Earnings Details
11/13/2014Q3 2014($0.24)($0.19)$4.67 millionViewN/AView Earnings Details
8/4/2014Q2 2014($0.22)($0.21)$3.30 million$4.21 millionViewN/AView Earnings Details
4/30/2014Q1 2014($0.26)($0.24)$2.75 million$3.14 millionViewN/AView Earnings Details
3/6/2014($0.22)($0.24)$3.17 million$2.99 millionViewN/AView Earnings Details
10/30/2013Q3 2013($0.20)($0.25)$3.07 million$2.96 millionViewN/AView Earnings Details
8/14/2013Q2 2013($0.31)$2.86 million$2.86 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.26)($0.31)$2.53 million$2.14 millionViewN/AView Earnings Details
3/12/2013Q4 2012($0.23)($0.36)ViewN/AView Earnings Details
11/7/2012Q3 2012($0.17)($0.20)ViewN/AView Earnings Details
8/14/2012Q2 2012($0.19)($0.15)ViewN/AView Earnings Details
5/14/2012Q1 2012($0.19)($0.19)ViewN/AView Earnings Details
11/9/2011Q3 2011($2.60)ViewN/AView Earnings Details
8/11/2011Q2 2011$0.06ViewN/AView Earnings Details
5/17/2011Q1 2011$0.21ViewN/AView Earnings Details
3/30/2011Q4 2010($0.09)ViewN/AView Earnings Details
11/15/2010Q3 2010($0.11)ViewN/AView Earnings Details
8/16/2010Q2 2010($0.05)ViewN/AView Earnings Details
5/17/2010Q1 2010($0.06)ViewN/AView Earnings Details
3/31/2009Q4 2008($0.02)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

AxoGen (NASDAQ:AXGN) Earnings Estimates

2018 EPS Consensus Estimate: ($0.20)
2019 EPS Consensus Estimate: ($0.10)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184($0.10)$0.01($0.06)
Q2 20184($0.07)$0.03($0.03)
Q3 20184($0.08)$0.04($0.04)
Q4 20183($0.09)($0.05)($0.07)
Q1 20192($0.04)($0.04)($0.04)
Q2 20192($0.04)($0.04)($0.04)
Q3 20192($0.04)($0.02)($0.03)
Q4 20191$0.01$0.01$0.01
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for AxoGen (NASDAQ:AXGN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

AxoGen (NASDAQ AXGN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.33%
Institutional Ownership Percentage: 69.57%
Insider Trades by Quarter for AxoGen (NASDAQ:AXGN)
Institutional Ownership by Quarter for AxoGen (NASDAQ:AXGN)

AxoGen (NASDAQ AXGN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/20/2018Jamie Mark GroomsDirectorSell63,395$27.67$1,754,139.65View SEC Filing  
2/15/2018Jamie Mark GroomsCFOSell95,712$26.84$2,568,910.08View SEC Filing  
2/13/2018Jamie Mark GroomsCFOSell10,300$26.21$269,963.00View SEC Filing  
12/12/2017Jamie Mark GroomsDirectorSell38,405$26.35$1,011,971.75View SEC Filing  
12/8/2017Jamie Mark GroomsDirectorSell84,295$26.38$2,223,702.10View SEC Filing  
12/6/2017Jamie Mark GroomsDirectorSell21,290$26.22$558,223.80View SEC Filing  
11/20/2017Guido J NeelsDirectorSell1,150,000$19.74$22,701,000.00View SEC Filing  
9/11/2017Robert James RudeliusDirectorSell16,143$18.00$290,574.0043,273View SEC Filing  
10/7/2016Amy Mcbride WendellDirectorBuy13,333$7.50$99,997.5013,333View SEC Filing  
10/7/2016John P EngelsVPBuy4,000$7.50$30,000.0098,425View SEC Filing  
10/7/2016Karen L ZaderejCEOBuy10,000$7.50$75,000.00242,147View SEC Filing  
10/7/2016Peter J MarianiCFOBuy3,333$7.50$24,997.503,333View SEC Filing  
8/9/2016Joseph M MandatoDirectorSell149,618$8.54$1,277,737.72View SEC Filing  
8/8/2016Joseph M MandatoDirectorSell107,450$8.63$927,293.50View SEC Filing  
7/21/2016James E FlynnInsiderSell102,136$6.70$684,311.20View SEC Filing  
7/18/2016James E FlynnInsiderSell279,303$7.53$2,103,151.59View SEC Filing  
9/18/2015James E FlynnInsiderSell345,000$5.50$1,897,500.00View SEC Filing  
6/3/2015Joseph M MandatoDirectorBuy6,500$3.10$20,150.00View SEC Filing  
6/2/2015Lee Robert Johnston JrInsiderBuy5,000$3.06$15,300.00View SEC Filing  
4/8/2015James E FlynnInsiderSell144,385$3.25$469,251.25View SEC Filing  
12/10/2014Lee Robert Johnston JrCFOBuy10,000$3.06$30,600.00View SEC Filing  
8/12/2014Mark Stephen GoldDirectorBuy20,000$2.29$45,800.00View SEC Filing  
8/8/2014Mark Stephen GoldDirectorBuy11,000$2.31$25,410.00View SEC Filing  
6/6/2014Lee Robert Johnston JrCFOBuy10,000$2.58$25,800.00View SEC Filing  
6/3/2014Gregory Gene FreitagCFOBuy5,200$2.45$12,740.00View SEC Filing  
6/3/2014Karen L ZaderejCEOBuy5,000$2.43$12,150.00View SEC Filing  
5/20/2014Jill F SchiaparelliSVPBuy2,000$2.63$5,260.00View SEC Filing  
5/12/2014Karen L ZaderejCEOBuy5,000$2.70$13,500.00View SEC Filing  
5/7/2014Mark Stephen GoldDirectorBuy1,977$2.60$5,140.20View SEC Filing  
3/13/2014Karen L ZaderejCEOBuy1,500$3.49$5,235.00View SEC Filing  
8/29/2013Shawn F MccarreySVPBuy25,000$3.21$80,250.00View SEC Filing  
8/24/2013Shawn F MccarreySVPBuy5,000$3.00$15,000.00View SEC Filing  
8/14/2013Jill F SchiaparelliSVPBuy5,000$3.00$15,000.00View SEC Filing  
8/14/2013John Frederick HarperDirectorBuy66,666$3.00$199,998.00View SEC Filing  
8/14/2013Karen L ZaderejCEOBuy8,334$3.00$25,002.00View SEC Filing  
12/4/2012Jill F SchiaparelliSVPBuy2,000$2.55$5,100.00View SEC Filing  
11/29/2012Jill F SchiaparelliSVPBuy1,000$2.70$2,700.00View SEC Filing  
11/15/2012Jill F SchiaparelliSVPBuy2,750$2.56$7,040.00View SEC Filing  
10/1/2012John Frederick HarperDirectorBuy86,557$3.61$312,470.77View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

AxoGen (NASDAQ AXGN) News Headlines

Source:
DateHeadline
AxoGen, Inc. (AXGN) Director Jamie Mark Grooms Sells 63,395 SharesAxoGen, Inc. (AXGN) Director Jamie Mark Grooms Sells 63,395 Shares
www.americanbankingnews.com - February 20 at 9:10 PM
Financial Survey: AxoGen (AXGN) vs. Zynex (ZYXI)Financial Survey: AxoGen (AXGN) vs. Zynex (ZYXI)
www.americanbankingnews.com - February 20 at 3:20 PM
AxoGen, Inc. to Present at Canaccord Genuity Musculoskeletal ConferenceAxoGen, Inc. to Present at Canaccord Genuity Musculoskeletal Conference
finance.yahoo.com - February 20 at 9:06 AM
AxoGen, Inc. (AXGN) CFO Jamie Mark Grooms Sells 10,300 SharesAxoGen, Inc. (AXGN) CFO Jamie Mark Grooms Sells 10,300 Shares
www.americanbankingnews.com - February 15 at 9:44 PM
Analyzing AxoGen (AXGN) & Zynex (ZYXI)Analyzing AxoGen (AXGN) & Zynex (ZYXI)
www.americanbankingnews.com - February 15 at 9:12 PM
Jamie Mark Grooms Sells 95,712 Shares of AxoGen, Inc. (AXGN) StockJamie Mark Grooms Sells 95,712 Shares of AxoGen, Inc. (AXGN) Stock
www.americanbankingnews.com - February 15 at 9:08 PM
AxoGen, Inc. to Report Fourth Quarter and Full-Year 2017 Financial Results and Host Conference Call on February 28, 2018AxoGen, Inc. to Report Fourth Quarter and Full-Year 2017 Financial Results and Host Conference Call on February 28, 2018
feeds.benzinga.com - February 14 at 7:49 AM
Financial Review: AxoGen (AXGN) & Zynex (ZYXI)Financial Review: AxoGen (AXGN) & Zynex (ZYXI)
www.americanbankingnews.com - February 10 at 3:14 PM
AxoGen, Inc. (AXGN) Receives Consensus Recommendation of "Buy" from AnalystsAxoGen, Inc. (AXGN) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - February 10 at 9:10 AM
$16.09 Million in Sales Expected for AxoGen, Inc. (AXGN) This Quarter$16.09 Million in Sales Expected for AxoGen, Inc. (AXGN) This Quarter
www.americanbankingnews.com - February 9 at 4:30 AM
-$0.09 Earnings Per Share Expected for AxoGen, Inc. (AXGN) This Quarter-$0.09 Earnings Per Share Expected for AxoGen, Inc. (AXGN) This Quarter
www.americanbankingnews.com - February 7 at 9:52 AM
William Blair Comments on AxoGen, Inc.s FY2017 Earnings (AXGN)William Blair Comments on AxoGen, Inc.'s FY2017 Earnings (AXGN)
www.americanbankingnews.com - February 7 at 8:56 AM
Head to Head Survey: Zynex (ZYXI) versus AxoGen (AXGN)Head to Head Survey: Zynex (ZYXI) versus AxoGen (AXGN)
www.americanbankingnews.com - February 6 at 9:14 AM
William Blairs Got Nerve: Initiates AxoGen Coverage With OutperformWilliam Blair's Got Nerve: Initiates AxoGen Coverage With Outperform
finance.yahoo.com - February 6 at 9:07 AM
AxoGen (AXGN) vs. Zynex (ZYXI) Financial ComparisonAxoGen (AXGN) vs. Zynex (ZYXI) Financial Comparison
www.americanbankingnews.com - February 6 at 1:14 AM
AxoGen (AXGN) Coverage Initiated by Analysts at William BlairAxoGen (AXGN) Coverage Initiated by Analysts at William Blair
www.americanbankingnews.com - February 5 at 9:48 PM
AxoGen, Inc. to Present at the LEERINK Partners 7th Annual Global Healthcare ConferenceAxoGen, Inc. to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 1 at 9:14 AM
$16.07 Million in Sales Expected for AxoGen, Inc. (AXGN) This Quarter$16.07 Million in Sales Expected for AxoGen, Inc. (AXGN) This Quarter
www.americanbankingnews.com - January 23 at 11:34 AM
AxoGen, Inc. (AXGN) Expected to Post Earnings of -$0.09 Per ShareAxoGen, Inc. (AXGN) Expected to Post Earnings of -$0.09 Per Share
www.americanbankingnews.com - January 21 at 1:08 PM
AxoGen, Inc. (AXGN) Given Average Recommendation of "Buy" by BrokeragesAxoGen, Inc. (AXGN) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 16 at 8:32 AM
AxoGen, Inc. (AXGN) to Post FY2017 Earnings of ($0.31) Per Share, Cantor Fitzgerald ForecastsAxoGen, Inc. (AXGN) to Post FY2017 Earnings of ($0.31) Per Share, Cantor Fitzgerald Forecasts
www.americanbankingnews.com - January 10 at 6:58 AM
AxoGen (AXGN) Reports Prelim 4Q & FY17 Revenues Slightly Above Consensus; Reiterates 2018 Revenue & Gross ... - StreetInsider.comAxoGen (AXGN) Reports Prelim 4Q & FY17 Revenues Slightly Above Consensus; Reiterates 2018 Revenue & Gross ... - StreetInsider.com
www.streetinsider.com - January 8 at 3:50 PM
Cantor Fitzgerald Analysts Give AxoGen (AXGN) a $37.00 Price TargetCantor Fitzgerald Analysts Give AxoGen (AXGN) a $37.00 Price Target
www.americanbankingnews.com - January 8 at 11:50 AM
AxoGen, Inc. Preannounces Estimated Fourth Quarter and Full Year 2017 RevenueAxoGen, Inc. Preannounces Estimated Fourth Quarter and Full Year 2017 Revenue
finance.yahoo.com - January 8 at 8:47 AM
AxoGen (AXGN) Rating Reiterated by Cantor FitzgeraldAxoGen (AXGN) Rating Reiterated by Cantor Fitzgerald
www.americanbankingnews.com - January 6 at 11:50 PM
ETFs with exposure to AxoGen, Inc. : December 29, 2017ETFs with exposure to AxoGen, Inc. : December 29, 2017
finance.yahoo.com - December 29 at 3:44 PM
AxoGen, Inc. (AXGN) Given Consensus Rating of "Buy" by BrokeragesAxoGen, Inc. (AXGN) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - December 22 at 8:50 AM
ETFs with exposure to AxoGen, Inc. : December 18, 2017ETFs with exposure to AxoGen, Inc. : December 18, 2017
finance.yahoo.com - December 18 at 3:44 PM
AxoGen Corporation Announces Avance® Nerve Graft Recipient Selected to Ride on Donate Life Rose Parade® FloatAxoGen Corporation Announces Avance® Nerve Graft Recipient Selected to Ride on Donate Life Rose Parade® Float
finance.yahoo.com - December 18 at 11:49 AM
December Top Growth Stocks To Look Out ForDecember Top Growth Stocks To Look Out For
finance.yahoo.com - December 17 at 11:07 AM
Comparing Integer (ITGR) & AxoGen (AXGN)Comparing Integer (ITGR) & AxoGen (AXGN)
www.americanbankingnews.com - December 14 at 9:52 AM
AxoGen, Inc. (AXGN) Director Sells $1,011,971.75 in StockAxoGen, Inc. (AXGN) Director Sells $1,011,971.75 in Stock
www.americanbankingnews.com - December 13 at 9:28 PM
AxoGen (AXGN) vs. Integer (ITGR) Head-To-Head ReviewAxoGen (AXGN) vs. Integer (ITGR) Head-To-Head Review
www.americanbankingnews.com - December 12 at 1:40 PM
AxoGen (AXGN) versus Integer (ITGR) Critical ReviewAxoGen (AXGN) versus Integer (ITGR) Critical Review
www.americanbankingnews.com - December 10 at 12:14 PM
Reviewing AxoGen (AXGN) and Arch Therapeutics (ARTH)Reviewing AxoGen (AXGN) and Arch Therapeutics (ARTH)
www.americanbankingnews.com - December 10 at 3:50 AM
Analyzing Integer (ITGR) and AxoGen (AXGN)Analyzing Integer (ITGR) and AxoGen (AXGN)
www.americanbankingnews.com - December 9 at 8:26 AM
Insider Selling: AxoGen, Inc. (AXGN) Director Sells 21,290 Shares of StockInsider Selling: AxoGen, Inc. (AXGN) Director Sells 21,290 Shares of Stock
www.americanbankingnews.com - December 8 at 11:16 PM
AxoGen, Inc. (AXGN) Director Jamie Mark Grooms Sells 84,295 SharesAxoGen, Inc. (AXGN) Director Jamie Mark Grooms Sells 84,295 Shares
www.americanbankingnews.com - December 8 at 8:28 PM
Critical Review: AxoGen (AXGN) and Arch Therapeutics (ARTH)Critical Review: AxoGen (AXGN) and Arch Therapeutics (ARTH)
www.americanbankingnews.com - December 7 at 7:28 PM
AxoGen, Inc. (AXGN) to Post FY2017 Earnings of ($0.33) Per Share, Jefferies Group ForecastsAxoGen, Inc. (AXGN) to Post FY2017 Earnings of ($0.33) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - December 4 at 2:22 AM
$16.06 Million in Sales Expected for AxoGen, Inc. (AXGN) This Quarter$16.06 Million in Sales Expected for AxoGen, Inc. (AXGN) This Quarter
www.americanbankingnews.com - December 3 at 12:28 PM
ETFs with exposure to AxoGen, Inc. : December 1, 2017ETFs with exposure to AxoGen, Inc. : December 1, 2017
finance.yahoo.com - December 1 at 6:27 PM
AxoGen (AXGN) Receives New Coverage from Analysts at Jefferies GroupAxoGen (AXGN) Receives New Coverage from Analysts at Jefferies Group
www.americanbankingnews.com - November 30 at 6:10 PM
AxoGen, Inc. (AXGN) Given Average Rating of "Buy" by AnalystsAxoGen, Inc. (AXGN) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - November 27 at 7:46 AM
Contrasting Integer (ITGR) and AxoGen (AXGN)Contrasting Integer (ITGR) and AxoGen (AXGN)
www.americanbankingnews.com - November 26 at 9:20 PM
Q2 2018 EPS Estimates for AxoGen, Inc. Decreased by Leerink Swann (AXGN)Q2 2018 EPS Estimates for AxoGen, Inc. Decreased by Leerink Swann (AXGN)
www.americanbankingnews.com - November 23 at 1:26 PM
Financial Analysis: Integer Holdings Corporation (ITGR) versus AxoGen (AXGN)Financial Analysis: Integer Holdings Corporation (ITGR) versus AxoGen (AXGN)
www.americanbankingnews.com - November 22 at 1:23 PM
AxoGen, Inc. (Nasdaq: AXGN) to Ring The Nasdaq Stock Market Opening Bell - GlobeNewswire (press release)AxoGen, Inc. (Nasdaq: AXGN) to Ring The Nasdaq Stock Market Opening Bell - GlobeNewswire (press release)
globenewswire.com - November 22 at 2:51 AM
AxoGen, Inc. (AXGN) PT Raised to $27 at Wedbush Following ... - StreetInsider.comAxoGen, Inc. (AXGN) PT Raised to $27 at Wedbush Following ... - StreetInsider.com
www.streetinsider.com - November 21 at 9:50 PM
AxoGen, Inc. (AXGN) PT Raised to $27 at JMP Securities Following Analyst Day - StreetInsider.comAxoGen, Inc. (AXGN) PT Raised to $27 at JMP Securities Following Analyst Day - StreetInsider.com
www.streetinsider.com - November 21 at 9:50 PM

SEC Filings

AxoGen (NASDAQ:AXGN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AxoGen (NASDAQ:AXGN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AxoGen (NASDAQ AXGN) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.